Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABLYFNASDAQ:GMABOTCMKTS:GNMSFNASDAQ:ITCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/AGMABGenmab A/S$21.25+0.3%$19.84$17.24▼$28.96$13.67B1.041.13 million shs160,241 shsGNMSFGenmab A/S$209.75-0.2%$196.07$170.00▼$292.80$13.86B1.022,875 shs61 shsITCIIntra-Cellular Therapies$131.87$131.86$64.72▼$131.98$14.05B0.691.53 million shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%GMABGenmab A/S-0.42%+3.27%+2.71%-6.78%-24.35%GNMSFGenmab A/S-0.17%+0.67%+2.71%-7.57%-27.66%ITCIIntra-Cellular Therapies0.00%0.00%0.00%+2.82%+100.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABLYFAblynxN/AN/AN/AN/AN/AN/AN/AN/AGMABGenmab A/S3.4025 of 5 stars3.33.00.00.02.80.03.1GNMSFGenmab A/S0.2646 of 5 stars0.01.00.00.01.90.01.3ITCIIntra-Cellular Therapies0.6534 of 5 stars1.10.00.04.50.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABLYFAblynx 0.00N/AN/AN/AGMABGenmab A/S 2.69Moderate Buy$39.1784.31% UpsideGNMSFGenmab A/S 0.00N/AN/AN/AITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideCurrent Analyst Ratings BreakdownLatest ABLYF, GNMSF, ITCI, and GMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $37.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.004/1/2025GMABGenmab A/SSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform3/11/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.003/11/2025GMABGenmab A/SWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABLYFAblynx$62.73M60.74N/AN/A$2.71 per share18.68GMABGenmab A/S$3.12B4.37$1.44 per share14.80$8.04 per share2.64GNMSFGenmab A/S$3.12B4.44$14.28 per share14.69$80.53 per share2.60ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABLYFAblynx-$122.67MN/A0.00∞N/AN/AN/AN/AN/AGMABGenmab A/S$1.14B$1.7612.2611.942.6536.30%16.78%13.79%8/14/2025 (Estimated)GNMSFGenmab A/S$1.14B$17.6311.97∞N/A36.30%19.75%16.23%8/7/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ALatest ABLYF, GNMSF, ITCI, and GMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/8/2025Q1 2025GNMSFGenmab A/S$1.88$3.05+$1.17$3.05$761.09 million$765.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABLYFAblynxN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/AGNMSFGenmab A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABLYFAblynxN/AN/AN/AGMABGenmab A/SN/A5.255.24GNMSFGenmab A/SN/A5.255.24ITCIIntra-Cellular TherapiesN/A7.667.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABLYFAblynxN/AGMABGenmab A/S7.07%GNMSFGenmab A/SN/AITCIIntra-Cellular Therapies92.33%Insider OwnershipCompanyInsider OwnershipABLYFAblynxN/AGMABGenmab A/S1.54%GNMSFGenmab A/S1.54%ITCIIntra-Cellular Therapies2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABLYFAblynxN/A75.25 millionN/ANot OptionableGMABGenmab A/S1,660641.20 million651.58 millionOptionableGNMSFGenmab A/S1,66066.08 million65.06 millionNot OptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableABLYF, GNMSF, ITCI, and GMAB HeadlinesRecent News About These CompaniesIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $109.70 Average Price Target from AnalystsMay 22, 2025 | americanbankingnews.comPaul Tudor Jones Makes Bold Move with iShares Russell 2000 ETFMay 15, 2025 | finance.yahoo.comInsight into Gabelli's First Quarter 2025 Portfolio AdjustmentsMay 15, 2025 | finance.yahoo.comPhathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 1, 2025 | globenewswire.comJnJ closes Intra-Cellular Therapies acquisitionApril 3, 2025 | medicaldialogues.inIntra-Cellular Therapies (ITCI) Receives a Rating Update from a Top AnalystApril 3, 2025 | markets.businessinsider.com5ITCI : Demystifying Intra-Cellular Therapies: Insights From 6 Analyst...April 2, 2025 | benzinga.comWhich Is a Better Investment, Corcept Therapeutics Incorporated or Intra-Cellular Therapies, Inc. Stock?April 1, 2025 | aaii.comIntra-Cellular TherapiesMarch 29, 2025 | forbes.comIntra-Cellular Therapies announces proxy statement supplementMarch 20, 2025 | uk.investing.comIntra-Cellular Therapies Stock Hits All-Time High of $131.47March 18, 2025 | investing.comIs Intra-Cellular Therapies, Inc. (ITCI) a Best Biotech Stock According to Billionaires?March 18, 2025 | msn.comIntra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comIntra-Cellular Therapies Stock Hits All-Time High of $131.37March 11, 2025 | investing.comIntra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025March 1, 2025 | insidermonkey.comKuehn Law Encourages Investors of Intra-Cellular Therapies, Inc. to Contact Law FirmFebruary 26, 2025 | investing.comINTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCIFebruary 25, 2025 | businesswire.comIntra-Cellular downgraded to Neutral from Outperform at MizuhoFebruary 24, 2025 | markets.businessinsider.comMizuho Downgrades Intra-Cellular Therapies (ITCI)February 24, 2025 | msn.comITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to ShareholdersFebruary 24, 2025 | businesswire.comMarketBeat Week in Review – 01/13 - 01/17 (ITCI)January 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABLYF, GNMSF, ITCI, and GMAB Company DescriptionsAblynx OTCMKTS:ABLYF$50.63 0.00 (0.00%) As of 04/30/2019Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.Genmab A/S NASDAQ:GMAB$21.25 +0.06 (+0.29%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Genmab A/S OTCMKTS:GNMSF$209.75 -0.37 (-0.17%) As of 05/28/2025 02:50 PM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
